Compare Coinbase Global, Inc. (COIN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Novartis AG — how do they compare? Coinbase Global, Inc. trades at $181.27 (market cap $45.38B), while Novartis AG trades at $143.76 (market cap $268.57B). The key difference: Novartis AG is far larger — about 5.9× Coinbase Global, Inc.'s market cap, and Novartis AG pays a 3.31% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Novartis AG for 82 Days on average.
| COIN | NVS | |
|---|---|---|
Market Cap | $45.38B | $268.57B |
Volume | 11,013,940 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $387.00 | $168.62 |
52-Week Low | $141.09 | $121.80 |
Typical Hold Time | 78 Days | 82 Days |
Enterprise Value | $43.03B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coinbase Global (COIN) trades at $181.09, up 1.48% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported $7.18B revenue in 2025 with $1.26B net income, though recent quarterly earnings have missed expectations. Positive developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup, while analyst consensus remains bullish with a $211.91 price target.
The stock presents growth potential from expanding derivatives business and institutional partnerships, but faces risks from earnings volatility and crypto market exposure. With 55% analyst buy ratings and strong cash flow generation, COIN offers upside to price targets, though investors should monitor execution on profitability goals amid competitive pressures.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
